ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative369.29 M514.01 M358.4 M530.65 M406.21 M1.81 BRicerca e sviluppo240.5 M180.65 M1.1 B240.7 M213.91 M1.73 BReddito operativo190.77 M-55.89 M-686.39 M57.51 M254.53 M-430.24 MProventi non operativi, Totale25.3 M27.39 M17.3 M18.7 M19.84 M83.23 MOneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari25.3 M27.39 M17.3 M18.7 M19.84 M83.23 MEntrate/uscite straordinarie——————Utile al lordo delle imposte133.2 M-110.35 M-735.64 M8.99 M208.41 M-628.59 MQuota di utile-16 K-542 K-86 K-47 K-57 K-732 KImposte-57.91 M-17.81 M-17.17 M-242.42 M4.96 M-272.44 MInteressi di minoranza——————Altri proventi/oneri al netto delle imposte1.64 M6.54 M-13.58 M-1.02 M4.96 M-3.1 MUtile netto al lordo delle attività cessate191.12 M-92.54 M-718.47 M251.41 M203.45 M-356.15 MAttività cessate——————Utile netto191.12 M-92.54 M-718.47 M251.41 M203.45 M-356.15 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari195.97 M-92.54 M-718.47 M251.41 M203.45 M-356.15 MUtile base per azione (EPS base)3.11-1.52-11.744.143.28-5.84Utile diluito per azione (EPS diluito)2.97-1.52-11.744.083.34-5.84Numero medio di azioni ordinarie in circolazione61.84 M60.98 M61.19 M60.7 M60.98 M243.85 MAzioni diluite in circolazione66.01 M60.98 M61.19 M61.61 M60.98 M244.76 MEBITDA827.6 M108.98 M-512.38 M235.75 M918.62 M750.98 MEBIT190.77 M-55.89 M-686.39 M57.51 M254.53 M-430.24 MCosto del fatturato——————Altri costi del venduto——————Ammortamento e svalutazione (liquidità)636.83 M164.87 M174.01 M178.25 M664.09 M1.18 B
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America.